---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-287727"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2022-11-17T23:59:59+00:00"
generated_at: "2026-06-21T16:47:21.759905+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acrivon Therapeutics completes IPO and concurrent $5M private placement with Chione Limited

## Summary
- Closed IPO and concurrent $5M private placement with Chione Limited on Nov 17, 2022.
- Issued 400,000 unregistered shares at $12.50/share to Chione under Section 4(a)(2) exemption.
- Filed amended certificate of incorporation and bylaws effective upon IPO closing.
- Shares in private placement are subject to lock-up and transfer restrictions; no public offering registration.

## SEC filing metadata
- accession: 0001193125-22-287727
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2022-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.02, 8.01, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312522287727/0001193125-22-287727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312522287727/d410573d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-287727
- JSON: https://secwatch.observer/filing/0001193125-22-287727.json
- Plain text: https://secwatch.observer/filing/0001193125-22-287727.txt

## Key facts
- Governance Changes
  Acrivon Therapeutics, Inc.: Amended and Restated Certificate of Incorporation filed in connection with IPO closing (effective 2022-11-17).
  - Change: charter amendment
  - Effective: 2022-11-17
  source text: On November 17, 2022, Acrivon Therapeutics, Inc. (the “Company”) filed an Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of its common stock (the “IPO”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312522287727/0001193125-22-287727-index.htm
- Governance Changes
  Acrivon Therapeutics, Inc.: Amended and Restated Bylaws adopted in connection with IPO closing (effective 2022-11-17).
  - Change: bylaw amendment
  - Effective: 2022-11-17
  source text: Effective as of November 17, 2022, the Company adopted Amended and Restated Bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312522287727/0001193125-22-287727-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.